SalaryGuide
SalariesCompaniesJobs
AboutPricingBlogFor Employers

Marketing jobs

7 marketing jobs

Teva Pharmaceuticals logo
3 weeks ago

Director, Marketing - Schizophrenia Consumer Marketing

Teva Pharmaceuticals

Parsippany, NJ (On-site)Full time$182K/yr – $227K/yr
Teva Pharmaceuticals logo
3 months ago

Director, CRM & Marketing Technology Strategy

Teva Pharmaceuticals

Parsippany, NJ (On-site)Full time$161K/yr – $202K/yr
Teva Pharmaceuticals logo
3 months ago

Sr Manager, Non-Traditional Generics Marketing

Teva Pharmaceuticals

Parsippany, NJ (Hybrid)Full time$133K/yr – $166K/yr
Teva Pharmaceuticals logo
3 months ago

Associate Director Marketing, HCP Medical Education

Teva Pharmaceuticals

Parsippany, NJ (On-site)Full time$154K/yr – $202K/yr
Teva Pharmaceuticals logo
3 months ago

Director UZEDY Marketing HCP Promotion

Teva Pharmaceuticals

Parsippany, NJ (On-site)Full time$182K/yr – $239K/yr
Teva Pharmaceuticals logo
4 months ago

Director, Marketing - Launch Lead

Teva Pharmaceuticals

New Jersey, USA (Unknown)$182K/yr – $239K/yr
Teva Pharmaceuticals logo
7 months ago

Director, Omnichannel Marketing

Teva Pharmaceuticals

Southwest Ranches, FL (On-site)Full time

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

7 jobs
Teva Pharmaceuticals logo

Director, Marketing - Schizophrenia Consumer Marketing

Teva Pharmaceuticals

Parsippany, NJ (On-site)

$182K/yr - $227K/yrIn-houseFull-timeDirector/executive10+ years exp.
3 weeks ago
Teva Pharmaceuticals logo

Director, CRM & Marketing Technology Strategy

Teva Pharmaceuticals

Parsippany, NJ (On-site)

$161K/yr - $202K/yrIn-houseFull-timeDirector/executive10+ years exp.
3 months ago
Teva Pharmaceuticals logo

Sr Manager, Non-Traditional Generics Marketing

Teva Pharmaceuticals

Parsippany, NJ (Hybrid)

$133K/yr - $166K/yrIn-houseFull-timeSenior level5+ years exp.
3 months ago
Teva Pharmaceuticals logo

Associate Director Marketing, HCP Medical Education

Teva Pharmaceuticals

Parsippany, NJ (On-site)

$154K/yr - $202K/yrIn-houseFull-timeManager7+ years exp.
3 months ago
Teva Pharmaceuticals logo

Director UZEDY Marketing HCP Promotion

Teva Pharmaceuticals

Parsippany, NJ (On-site)

$182K/yr - $239K/yrIn-houseFull-timeDirector/executive10+ years exp.
3 months ago
Teva Pharmaceuticals logo

Director, Marketing - Launch Lead

Teva Pharmaceuticals

New Jersey, USA (Unknown)

$182K/yr - $239K/yrIn-houseDirector/executive10+ years exp.
4 months ago
Teva Pharmaceuticals logo

Director, Omnichannel Marketing

Teva Pharmaceuticals

Southwest Ranches, FL (On-site)

In-houseFull-timeDirector/executive8+ years exp.
7 months ago
Teva Pharmaceuticals logo
Teva Pharmaceuticals

Director, Marketing - Schizophrenia Consumer Marketing

Parsippany, NJ (On-site)

$182K/yr – $227K/yrDirector/Executive10+ years expFull time

Posted 3 weeks ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Lead the patient and caregiver marketing strategy for a Schizophrenia portfolio, shaping journeys, omni-channel promotions, and cross-functional collaboration to improve engagement and outcomes.

  • Own brand strategy translation into branded and unbranded consumer plans
  • Drive integrated patient experiences across awareness to ongoing support
  • Partner with cross-functional teams to optimize KPIs and ROI

Job Description

Responsibilities

  • Lead a team of marketers to develop and implement a patient and caregiver marketing strategy across the Schizophrenia portfolio, including patient promotion, education, engagement, and consumer portfolio and brand planning.
  • Collaborate with brand leads to translate brand strategy, positioning, and priorities into aligned branded and unbranded consumer plans, messages, and multichannel promotions.
  • Partner closely with Patient Services to design and deliver an integrated consumer experience spanning awareness, treatment consideration, onboarding, access, affordability, initiation, adherence, and ongoing support.
  • Develop patient and caregiver journeys, personas, segmentation, and insight frameworks that identify unmet needs, barriers, moments that matter, and opportunities to improve engagement and treatment experience.
  • Lead the development and execution of effective, compliant consumer promotions across digital, social, CRM, media, print, field, and patient-support channels, ensuring a consistent and connected experience.
  • Integrate patient and caregiver insights into brand planning and execution by partnering with Market Research, Analytics, Advocacy, Market Access, Legal, Regulatory, Compliance, Sales, and external agencies.
  • Establish consumer marketing and experience KPIs, monitor campaign and program performance, and use data and insights to optimize engagement, conversion, onboarding, persistence, satisfaction, and return on investment.
  • Lead agency and vendor partners, including scope, budget, timelines, quality, and performance, while ensuring resources are allocated against the highest strategic priorities.
  • Lead, coach, and develop a high-performing patient marketing team and influence cross-functional partners outside the direct reporting line to deliver shared brand and patient-experience objectives.
  • Identify and scale opportunities to improve consistency, efficiency, innovation, and best-practice sharing across the Schizophrenia Franchise.

Requirements

  • ≥ 10 Years of pharmaceutical experience or relevant brand management experience
  • ≥ 5 Years of marketing experience or equivalent (based on performance)
  • Previous experience leading patient or consumer marketing strategy and multichannel promotion in the pharmaceutical or healthcare industry is preferred, including patient journey development, branded and unbranded communications, market research and analytics, agency management, and collaboration with Patient Services, patient hubs, specialty pharmacies, affordability programs, or access services.
  • Experience in schizophrenia or another complex specialty market and product launch experience are also preferred.
  • Previous experience with developing HCP Medical Education resources is preferred.
  • Demonstrated ability to develop patient-centered strategies and translate insights into effective consumer promotions and support experiences.
  • Proven ability to collaborate with brand leads, Patient Services, and other internal and external partners to deliver shared objectives.
  • Strong knowledge of pharmaceutical promotional practices, review processes, and applicable legal, regulatory, and compliance requirements.
  • Analytical and project management skills, including the ability to establish KPIs, interpret performance data, manage budgets, and optimize multiple programs and assets.
  • Team leadership and people management skills, with the ability to build strong partnerships and identify the right mix of internal and external talent.

Preferred

  • Previous experience leading patient or consumer marketing strategy and multichannel promotion in the pharmaceutical or healthcare industry is preferred, including patient journey development, branded and unbranded communications, market research and analytics, agency management, and collaboration with Patient Services, patient hubs, specialty pharmacies, affordability programs, or access services.
  • Experience in schizophrenia or another complex specialty market and product launch experience are also preferred.
  • Previous experience with developing HCP Medical Education resources is preferred.

Benefits

  • Comprehensive Health Insurance: Medical, Dental, Vision, and Prescription coverage starting on the first day of employment, providing the employee enrolls.
  • Retirement Savings: 401(k) with employer match, up to 6% and an annual 3.75% Defined Contribution to the 401k plan.
  • Time Off: Paid Time Off including vacation, sick/safe time, caretaker time and holidays.
  • Life and Disability Protection: Company paid Life and Disability insurance.
  • Additional benefits include, but are not limited to, Employee Assistance Program, Employee Stock Purchase Plan, Tuition Assistance, Flexible Spending Accounts, Health Savings Account, Life Style Spending Account, Volunteer Time Off, Paid Parental Leave, if eligible , Family Building Benefits, Virtual Physical Therapy, Accident, Critical Illness and Hospital Indemnity Insurances, Identity Theft Protection, Legal Plan, Voluntary Life Insurance and Long Term Disability and more.
Teva Pharmaceuticals logo

Teva Pharmaceuticals

3.6 Glassdoor

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Founded in 1901
Tel Aviv-Yafo, Tel Aviv District, ISR
30K employees (1,056 in marketing)
www.tevapharm.com
70% recommend to a friend
82% CEO approval

Salaries

Posted range

$182K/yr – $227K/yr

Taken straight from the job posting.

See all Teva Pharmaceuticals salaries

Marketing Team

Marketing Team Size
826 (3% of company)
Median Career Experience
12 years
Median Tenure
5.6 years
Marketing Roles Posted (Last 30 Days)
1

People

Marketing Leadership

Jillian Connolly
Jillian Connolly
Associate Director, HCP Marketing
At the company for 8 months

Funding

Total Funding
$5.5B
Last Raise
$400M
Post IPO Equity, 2 months ago

Funding History

  • Mar 2026
    Post IPO Equity • $400M
  • Jan 2026
    Post IPO Equity • $500M
  • May 2025
    Post IPO Debt • $2.3B

Traffic Signals

Monthly Visitors
115.6K
Traffic Source Mix
Search
54.6%
Direct
32.5%
Referral
8.7%
Social
2.2%
Paid
1.1%

Headcount Trend

Current headcount: ~30K

Recent News

Should We Be Cautious About Teva Pharmaceutical Industries Limited's (NYSE:TEVA) ROE Of 9.1%?
Dec 5, 2025 • Yahoo Finance
Teva seeks startups to help solve global pharmaceutical challenges
Nov 19, 2025 • Reuters
Teva calls on startups to Rise to the occasion with open innovation platform for 7 biopharma challenges
Nov 19, 2025 • Fierce Pharma
We Think Teva Pharmaceutical Industries' (NYSE:TEVA) Healthy Earnings Might Be Conservative
Nov 13, 2025 • simplywall.st
Teva Pharma stock hits 52-week high at $25.96
Nov 13, 2025 • Investing.com
We Like The Quality Of Teva Pharmaceutical Industries' (NYSE:TEVA) Earnings
Nov 12, 2025 • Yahoo Finance
Teva Hits Profit-Taking Zone On Austedo's Big Sales Beat
Nov 5, 2025 • Investor's Business Daily
Teva CEO touts 'defining strength' of innovative drugs as its sales grow for 11th straight quarter
Nov 5, 2025 • Fierce Pharma
Teva Pharmaceutical Industries Ltd reports results for the quarter ended September 30 - Earnings Summary
Nov 5, 2025 • TradingView
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2025 Earnings Call Highlights: Strong Growth ...
Nov 5, 2025 • Yahoo Finance
Earnings call transcript: Teva beats Q3 2025 forecasts, stock surges
Nov 5, 2025 • Investing.com
Why Teva Pharmaceutical Stock Rocked the Market Today
Nov 5, 2025 • The Motley Fool
Teva shares soar on strong third-quarter performance
Nov 5, 2025 • CTech
Teva Pharm profit tops estimates, says not worried by US tariffs
Nov 5, 2025 • Reuters
Seeking Clues to Teva Pharmaceutical Industries (TEVA) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Nov 4, 2025 • Yahoo Finance
Is Teva a Value Opportunity After Recent 8.1% Share Price Jump?
Nov 2, 2025 • simplywall.st
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation: Is There Untapped Value After Recent Uptrend?
Oct 30, 2025 • Yahoo Finance
Teva Pharmaceutical (TEVA) Enters Into a License Agreement With Prestige Biopharma for the Commercialization of Tuznue in Europe
Oct 24, 2025 • Yahoo Finance
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Oct 22, 2025 • Yahoo Finance
Does Teva Pharmaceutical Industries (TEVA) Have the Potential to Rally 28.12% as Wall Street Analysts Expect?
Oct 21, 2025 • Yahoo Finance
JPMorgan and UBS Raise PT for Teva Pharmaceutical (TEVA)
Oct 20, 2025 • Yahoo Finance
Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock
Oct 16, 2025 • Yahoo Finance
BofA Raises Teva Pharmaceutical (TEVA) PT to $24, Amid “Pivot to Growth” Strategy Execution
Oct 13, 2025 • Yahoo Finance
Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside (NYSE:TEVA)
Oct 7, 2025 • Seeking Alpha
Teva closes in on sale of API business TAPI
Oct 2, 2025 • European Pharmaceutical Review
UBS Maintains its Buy Rating on Teva Pharmaceutical Industries Limited (TEVA); Raises Its Price Target to $26.00
Oct 1, 2025 • Yahoo Finance
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term
Sep 30, 2025 • Nasdaq
JHX SHAREHOLDER ALERT: James Hardie Industries plc Investors may have been Affected by Fraud -- Contact BFA Law about its Investigation
Sep 26, 2025 • Bleichmar Fonti & Auld
TL1A Binder Market Set to Expand by 2034 with Key Players Such as Merck, Roche, Teva Pharmaceuticals, Sanofi, and Others Driving Multi-Indication Advancements | DelveInsight
Sep 25, 2025 • PR Newswire UK
TL1A Binder Market Set to Expand by 2034 with Key Players Such as Merck, Roche, Teva Pharmaceuticals, Sanofi, and Others Driving Multi-Indication Advancements | DelveInsight
Sep 25, 2025 • PR Newswire
Teva Releases Q3 2025 Aide Memoire
Sep 25, 2025 • BioSpace
Teva Releases Q3 2025 Aide Memoire
Sep 25, 2025 • Teva Pharmaceutical Industries Ltd
Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
Sep 25, 2025 • Teva Pharmaceutical Industries Ltd
Teva Pharma stock price target raised to $26 by UBS on Austedo outlook
Sep 24, 2025 • Investing.com
Enery signs 15-year PPA with Teva Bulgaria | Bulgaria Investments News
Sep 24, 2025 • SeeNews
Truist Securities reiterates Buy rating on Teva Pharma stock, maintains $25 price target
Sep 23, 2025 • Investing.com
Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®
Sep 23, 2025 • PharmiWeb
Bausch Health, Teva Hit With Xifaxan Pay-for-Delay Scheme Claims
Sep 23, 2025 • bloomberglaw.com
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Sep 22, 2025 • BioSpace
Teva Pharmaceutical Industries (NYSE:TEVA): Evaluating Valuation Potential After Recent Share Movement
Sep 21, 2025 • Yahoo Finance
Teva preesents 10 posters from its schizophrenia medicines portfolio
Sep 21, 2025 • thefly.com
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Sep 21, 2025 • thecanadianpressnews.ca
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Sep 21, 2025 • MarketScreener
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Sep 21, 2025 • Teva Pharmaceutical Industries Ltd
Roche to buy 89bio for up to $3.5b
Sep 18, 2025 • Globes
Teva’s SWOT analysis: pharma giant’s stock pivots to growth amid challenges
Sep 17, 2025 • Investing.com
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
Sep 17, 2025 • BioSpace
Teva Pharmaceutical Industries (TEVA) Attains FDA’s Fast Track Designation for Emrusolmin
Sep 16, 2025 • Yahoo Finance
FDA targets Lilly, Novartis, BMS and more in deluge of marketing letters
Sep 16, 2025 • FiercePharma
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
Sep 16, 2025 • Teva Pharmaceutical Industries Ltd
Belgian investors unknowingly back Israeli firms through bank funds
Sep 15, 2025 • belganewsagency.eu
J.P. Morgan Maintains a Buy on Teva Pharmaceutical (TEVA) With a $23 PT
Sep 11, 2025 • Yahoo Finance
Teva at Morgan Stanley Conference: Pivot to Growth Strategy
Sep 9, 2025 • Investing.com
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy
Sep 9, 2025 • GlobeNewswire
Teva Pharmaceutical Says US FDA Grants Emrusolmin Fast Track Designation for Multiple System Atrophy Treatment
Sep 9, 2025 • MarketScreener
WHO Adds GLP-1s to List of Essential Medicines
Sep 8, 2025 • BioSpace
Pro-Palestine protesters in Ireland, Northern Ireland call for boycott of Israeli goods
Sep 6, 2025 • Arab News
Medincell: Reminder of the Participation Terms in the Combined General Meeting
Sep 3, 2025 • PharmiWeb
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September
Sep 2, 2025 • Teva Pharmaceutical Industries Ltd
Teva wins FDA approval for first generic weight loss GLP-1
Sep 1, 2025 • BioXconomy
Teva Pharmaceutical Industries (TEVA) Announces the FDA Approval and U.S. Launch of Generic Saxenda
Aug 30, 2025 • Yahoo Finance
Teva wins US obesity approval for its GLP-1 generic liraglutide
Aug 29, 2025 • European Pharmaceutical Review
Seminar: IP That Matters - Behind Orexo’s Milestone Patent Win at the US Court
Aug 29, 2025 • News Powered by Cision
US FDA approves Teva Pharmaceuticals' generic obesity drug
Aug 28, 2025 • Reuters
With Saxenda generic, Teva launches first copycat GLP-1 for obesity
Aug 28, 2025 • Fierce Pharma
US FDA approves Teva Pharmaceuticals' generic obesity drug
Aug 28, 2025 • Reuters
Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda
Aug 28, 2025 • Benzinga.com
The Chip on America's Shoulder
Aug 28, 2025 • MarketScreener
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
Aug 28, 2025 • Teva Pharmaceutical Industries Ltd
Teva stock rises on launch of first generic weight loss GLP-1 drug
Aug 28, 2025 • Investing.com
Healthcare workers across Italy to hold hunger strike protest in solidarity with Gaza
Aug 27, 2025 • Wanted in Rome - News in Italy - Rome's local English news
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
Aug 26, 2025 • Morningstar.com
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
Aug 26, 2025 • BioSpace
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
Aug 25, 2025 • Business Wire
Piper Sandler Reiterates a Buy Rating on Teva Pharmaceutical Industries (TEVA)
Aug 25, 2025 • Yahoo Finance
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
Aug 25, 2025 • Catalyst Pharmaceuticals, Inc.
US Narcolepsy Drugs Market Outlook and Company Analysis Report 2025-2033 Featuring Jazz Pharma, Ligand Pharma, Novartis, Takeda Pharma, Teva, Hikma, Harmony Biosciences, Roche - ResearchAndMarkets.com
Aug 25, 2025 • Business Wire
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
Aug 25, 2025 • MarketScreener
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
Aug 25, 2025 • PharmiWeb
Stanley Druckenmiller builds Teva position. - Globes
Aug 24, 2025 • Globes - Israel Business News
Children’s Health Ireland demands end use Teva medication
Aug 23, 2025 • The Jerusalem Post
Biosimilars Market to Surpass US$ 171.79 Billion by 2033 - Exclusive Report by DataM Intelligence
Aug 22, 2025 • PR Newswire UK
Teva Pharmaceuticals’ Market Shift: Growth or Mirage?
Aug 21, 2025 • StocksToTrade
Deoxyribonucleic Acid (DNA) Repair Alkylating Agent Market to Reach US $5.05 Billion by 2029
Aug 21, 2025 • EIN Presswire
Outrage in Italy after medical staff seen discarding Israeli-made Teva medications
Aug 20, 2025 • Ynetnews
Common Cold Market to Reach $34.3 Billion by 2029 with 6.2% CAGR
Aug 20, 2025 • EIN Presswire
Fda says Teva Pharmaceuticals USA discontinues manufacture of Finasteride tablet, 5 mg
Aug 19, 2025 • MarketScreener
Earnings call transcript: Teva’s Q2 2025 earnings beat fails to lift revenue
Aug 18, 2025 • Investing.com
Global Women’s Health Market to Grow at 4–5% CAGR Driven by Disease Burden and Contraceptive Demand by 2030
Aug 18, 2025 • PharmiWeb
Teva Pharmaceuticals USA discontinues manufacturing of celecoxib, capsule, says FDA
Aug 15, 2025 • MarketScreener
2025 Q2 Job Market Report: Quartlery Job Postings Decline for Third Straight Quarter
Aug 15, 2025 • BioSpace
Vitamin B12 Market Set to Surpass USD 444.47 Million by 2030, Driven by Rising Veganism, Preventive Healthcare Focus, and Growth in Nutraceuticals: MarkNtel Advisors
Aug 14, 2025 • PR Newswire
Saudi Arabia Generic Drugs Market Outlook Report 2025-2033 | Government Cost-Cutting, Local Manufacturing, and Public Awareness Fuel Rapid Growth
Aug 14, 2025 • Research and Markets
United States Narcolepsy Drugs Market to Reach US$ 2,233.56 Million by 2033 - 7.88% CAGR Driven by Novel Therapies and Better Diagnosis
Aug 14, 2025 • Research and Markets
Senores Pharma to buy two ANDAs from Teva, its third US transaction this year
Aug 13, 2025 • Hindu Business Line
FDA approves AJOVY for paediatric migraine prevention
Aug 13, 2025 • Pharma Times
Cancer Pain Market Forecast to Hit US $10.32 billion by 2030 on Rising Demand & Cannabis-Driven Therapies
Aug 13, 2025 • EIN Presswire
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
Aug 13, 2025 • Research and Markets
Intelligent Asthma Monitoring Devices to Reach US $1.69 Bn by 2030 as AI-Driven Platforms Enhance Early Detection
Aug 13, 2025 • EIN Presswire
Triamterene Capsules Market set to hit $1437.5 million by 2035
Aug 12, 2025 • PRLog

Links

www.tevapharm.comLinkedInX (Twitter)Crunchbase

This role is listed on SalaryGuide for informational purposes. SalaryGuide is not the employer, recruitment agency, or hiring representative for this position. Hiring decisions and the application process are managed by the employer. SalaryGuide will never ask candidates to pay to apply for a job or request bank details or identification documents as part of an application.